The Midwest Comparative Effectiveness Public Advisory Council (Midwest CEPAC), a core program of the Institute for Clinical and Economic Review (ICER), is a nationally-recognized community forum. The Midwest CEPAC convenes three times each year at public meetings to review objective evidence reports and develop recommendations for how stakeholders can apply evidence to improve the quality and value of health care. Learn more about the Midwest CEPAC process, and Find out how topics are selected.

Midwest CEPAC directly engages clinicians, patients, and payers during public meetings to discuss implications of the evidence for clinical decision-making and coverage policies. Application of evidence takes shape through new medical policies, benefit designs, and patient and clinician tools to improve clinical care and patient outcomes. All members of the Midwest CEPAC must meet ICER’s criteria for Conflict of Interest.

The box below provides information on the topic of the next meeting of the Midwest CEPAC. For more information about past and other upcoming meetings, see the box to the right.

Next Meeting

May 17, 2018 10am-4pm CT

University of Missouri-St. Louis
Century BC Room, Millennium Student Center
1 University Boulevard
St. Louis, MO 63121

Cystic Fibrosis

The Midwest CEPAC will convene to discuss treatments for cystic fibrosis.


Cystic Fibrosis

Cystic fibrosis is an autosomal recessive condition caused by mutations in the CFTR gene. It is relatively rare, occurring in approximately 1 in 2,500 to 3,000 livebirths, but is the most common, lethal genetic disease in Caucasian populations. CF is a progressive disease that affects many organ systems, but most of its morbidity and mortality are associated with its impact on the respiratory system.

Interventions of Interest:

  • Tezacaftor/ivacaftor (SymdekoTM, Vertex Pharmaceuticals)
  • Lumacaftor/ivacaftor (Orkambi®, Vertex Pharmaceuticals)
  • Ivacaftor (Kalydeco®, Vertex Pharmaceuticals)
View materials


November 29, 2018 Asthma
September 13, 2018 Amyloidosis
September 13, 2018 Prostate Cancer
May 17, 2018 Cystic Fibrosis
January 25, 2018 Voretigene Neparvovec
September 14, 2017 Ovarian Cancer
May 25, 2017 Atopic Dermatitis
May 26, 2016 Multiple Myeloma
See more